Relay Therapeutics, Inc. (RLAY) is a Biotechnology company in the Healthcare sector, currently trading at $14.75. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is RLAY = $16 (+10.7% upside).
Valuation: RLAY trades at a trailing Price-to-Earnings (P/E) of -8.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.53.
Financials: revenue is $15M, +580.8%/yr average growth. Net income is $276M (loss), growing at -5%/yr. Net profit margin is -1800.6% (negative). Gross margin is 76.8% (+275.9 pp trend).
Balance sheet: total debt is $32M against $567M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 22.61 (strong liquidity). Debt-to-assets is 5.2%. Total assets: $621M.
Analyst outlook: 15 / 15 analysts rate RLAY as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 45/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).
